Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K K Adkison

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Opinion in Drug Discovery & Development|August 4, 2009
High-throughput screening for lead optimization: a rational approachM Bajpai, K K Adkison
Journal of Pharmaceutical Sciences|March 3, 1999
Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationshipsJ E Shaffer, K K Adkison, K Halm, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2013
Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjectsD A Wilfret, K K Adkison, L A Jones, et al.
Pharmaceutical Biotechnology|October 7, 1998
Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parametersK K Adkison, K A Halm, J E Shaffer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 31, 1998
Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbitsJ L Scism, K M Powers, A A Artru, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 1999
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonistsB R Henke, K K Adkison, S G Blanchard, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2013
Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1D A Wilfret, J Walker, K K Adkison, et al.
HIV Medicine|February 10, 2009
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)P Yeni, A Lamarca, D Berger, et al.
Clinical Pharmacology and Therapeutics|December 23, 2011
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1P Kasirye, L Kendall, K K Adkison, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Opinion in Drug Discovery & Development|August 4, 2009
High-throughput screening for lead optimization: a rational approachM Bajpai, K K Adkison
Journal of Pharmaceutical Sciences|March 3, 1999
Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationshipsJ E Shaffer, K K Adkison, K Halm, et al.
Antimicrobial Agents and Chemotherapy|July 17, 2013
Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjectsD A Wilfret, K K Adkison, L A Jones, et al.
Pharmaceutical Biotechnology|October 7, 1998
Discovery of a potent and selective alpha 1A antagonist. Utilization of a rapid screening method to obtain pharmacokinetic parametersK K Adkison, K A Halm, J E Shaffer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 31, 1998
Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbitsJ L Scism, K M Powers, A A Artru, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 1999
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonistsB R Henke, K K Adkison, S G Blanchard, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2013
Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1D A Wilfret, J Walker, K K Adkison, et al.
HIV Medicine|February 10, 2009
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)P Yeni, A Lamarca, D Berger, et al.
Clinical Pharmacology and Therapeutics|December 23, 2011
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1P Kasirye, L Kendall, K K Adkison, et al.
Pageof 1